Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091286 · ClinicalTrials.gov registry record · Early Phase 1
Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer
A Early Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT00091286: Clinical Trial Early Phase 1 study, sponsored by Craig L Slingluff, Jr.
NCT00091286 is a Early Phase 1 study that was terminated before completion, run by Craig L Slingluff, Jr. The registered enrollment target is 11 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091286, a Early Phase 1 study, was terminated before completion, sponsored by Craig L Slingluff, Jr.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with stage IIB, stage III, or stage IV colorectal cancer.
Primary Outcome
Adverse events
Interventions
- BIOLOGICAL HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2003-03-24 |
| Est. Completion | 2008-02-15 |
| Phase | Early Phase 1 |
Why NCT00091286 stopped before completion
NCT00091286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine is the first listed.
NCT00091286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00091286 about?
NCT00091286 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer". RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with stage IIB, stage III, or stage IV colorectal cancer.
What is the current status of trial NCT00091286?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2003-03-24. Estimated completion is 2008-02-15.
What interventions are being tested in trial NCT00091286?
The interventions under investigation include: HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00091286?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00091286's enrollment target sits among peer trials
11 1600th of 2000 higher than 373 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI